Nanopharm-logo-with-signature-Pantone (1)
Close this search box.

19 Jun 2018

Trade Marks Registration Certificate for Nanopharm Ltd


This certificate represents a significant milestone for Nanopharm Ltd, a company at the forefront of pharmaceutical research and analysis in OINDPs. It certifies the registration of the trade mark “NANOPHARM” under the Trade Marks Act 1994 of Great Britain and Northern Ireland. The certificate underscores Nanopharm’s commitment to the development of new pharmaceutical products and the provision of scientific laboratory services.

The certificate also highlights the range of services offered by Nanopharm, including chemical and pharmaceutical research, development of new pharmaceutical products for others, and provision of pharmaceutical information. It further emphasizes the company’s role in the collection of information relating to the use of pharmaceuticals and the provision of pharmaceutical consultation services.

The registration of the trade mark “NANOPHARM” is a testament to the company’s dedication to advancing the field of pharmaceutical research and development. It showcases the expertise and innovative services that Nanopharm brings to the exciting field of pharmaceutical analysis and consultation.

Related Posts


Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack

Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

Read More »